title: Participation of IL-4 in the formation of IgD-binding factors by antigen-primed mouse spleen cells.
abstract: BALB/c mouse spleen cells primed with either keyhole limpet hemocyanin or DNP-keyhole limpet hemocyanin formed not only IgG-binding factors (BF) and IgE-BF but also IgD-BF upon antigenic stimulation. Analysis of cellular mechanisms involved in the formation of Ig-BF by antigenic stimulation revealed that Ag-primed Th cells released lymphokines upon antigenic stimulation, and that the lymphokine(s) in turn stimulates unprimed T cells to form Ig-BF. Normal unprimed lymphocytes formed IgD-BF upon incubation with culture supernatants of Ag-stimulated spleen cells. The formation of IgD-BF induced by the culture supernatant was prevented by anti-IL-4 mAb (11B11). It was also found that 0.3 to 10 U/ml mouse rIL-4, but none of the rIL-1, IL-2, and IFN-gamma, induced normal T cells to form IgD-BF. Indeed, both IL-2 and IFN-gamma inhibited IL-4 to induce the formation of IgD-BF. In contrast, 10 to 50 U/ml of IFN-gamma induced the formation of IgE-BF, and 50 to 200 U/ml IFN-gamma induced the formation of IgG-BF. However, none of the other lymphokines tested, i.e., IL-1, IL-2, and IL-4, induced the formation of either IgE-BF or IgG-BF. The IgD-BF formed by antigenic stimulation of keyhole limpet hemocyanin-primed spleen cells and those formed by stimulation of normal lymphocytes with 1 to 2 U/ml IL-4 enhanced both IgM and IgG1 plaque-forming cell responses of SRBC-primed spleen cells to homologous Ag. In contrast, 1 to 2 U/ml of IL-4, which could induce the formation of IgD-BF, failed to affect the PFC responses. It appears that the formation of IgD-BF may be involved in the effects of IL-4 to enhance the antibody response.
authors.affiliation: Subdepartment of Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 21239.
authors.forename: M
authors.initials: M
authors.lastname: Adachi
authors.forename: N
authors.initials: N
authors.lastname: Arai
authors.forename: K
authors.initials: K
authors.lastname: Ishizaka
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D004136:Dinitrobenzenes / Q000276:immunology; D006241:Haptens / Q000008:administration & dosage* / Q000276:immunology; D006433:Hemocyanins / Q000276:immunology; D007072:Immunoglobulin D / Q000378:metabolism*; D015847:Interleukin-4; D007378:Interleukins / Q000096:biosynthesis / Q000502:physiology*; D008222:Lymphokines / Q000096:biosynthesis* / Q000502:physiology; D051379:Mice; D008807:Mice, Inbred BALB C; D029584:Prostatic Secretory Proteins; D011961:Receptors, Fc; D013154:Spleen / Q000166:cytology* / Q000276:immunology / Q000378:metabolism; D013601:T-Lymphocytes / Q000145:classification / Q000276:immunology / Q000378:metabolism
chemical_list: D004136:Dinitrobenzenes; C037317:Fc(delta) receptor; D006241:Haptens; D007072:Immunoglobulin D; D007378:Interleukins; D008222:Lymphokines; D029584:Prostatic Secretory Proteins; D011961:Receptors, Fc; C043076:beta-microseminoprotein; C013059:immunoglobulin-binding factors; D015847:Interleukin-4; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin